Compare Banco Santander SA (SAN) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Banco Santander SA vs Vertex Pharmaceuticals Incorporated — how do they compare? Banco Santander SA trades at $14.71 (market cap $218.36B), while Vertex Pharmaceuticals Incorporated trades at $522.29 (market cap $134.06B). The key difference: Banco Santander SA is the larger of the two by market cap, and Banco Santander SA pays a 1.87% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| SAN | VRTX | |
|---|---|---|
Market Cap | $218.36B | $134.06B |
Sector | Financials | Health |
52-Week High | $15.05 | $557.96 |
52-Week Low | $9.65 | $376.62 |
Dividend Yield | 1.87% | — |
Enterprise Value | — | $128.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Banco Santander (SAN) trades at $14.86, down 0.47% on the day, with a bullish technical signal from moving averages and a moderate buy consensus from analysts (64% buy ratings). The company reported record profitability in H1 2026 with a net income margin of 26.25% and recently completed the Webster acquisition to expand its U.S. presence, though cash flow trends show recent operational outflows.
SAN's outlook is supported by strong profitability and strategic expansion, but risks include volatile cash flows, high leverage with a debt-to-asset ratio of 17.8, and integration challenges from acquisitions. The stock offers value with a P/E of 14.47, but investors should weigh execution risks against growth potential.
Vertex Pharmaceuticals (VRTX) trades at $528.9, down 3.15% on the day, amid a mixed technical and fundamental backdrop. The stock shows a bullish moving average signal but neutral oscillators, with key support at $522. Fundamentally, 2025 revenue reached $12.0B with a strong net income margin of 35%, though recent quarterly EPS results have been mixed. The company recently completed the acquisition of Crinetics Pharmaceuticals, signaling growth ambitions.
The outlook remains positive given analyst consensus favoring a Buy rating (84%) and a $548.78 price target, implying upside. Key opportunities include revenue growth from new drug launches, while risks involve competitive pressures and earnings volatility. The stock's current valuation at a P/E of 30.8 requires sustained execution to justify further gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Banco Santander SA
Santander's focus is on retail and commercial banking. Latin America is geographically the largest operation, with Brazil by far the largest. Its continental European business is still mainly Iberian. Santander's U.K. presence is the result of the acquisition of building society Abbey. In the U.S., Santander operates a vehicle finance business and a regional bank focused on the Northeastern states.
Read more on SAN →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
